Provided by Tiger Trade Technology Pte. Ltd.

Anavex Life Sciences

2.85
-0.0400-1.38%
Post-market: 2.850.00000.00%19:30 EDT
Volume:421.92K
Turnover:1.21M
Market Cap:264.11M
PE:-19.71
High:2.94
Open:2.90
Low:2.82
Close:2.89
52wk High:10.40
52wk Low:2.26
Shares:92.67M
Float Shares:87.17M
Volume Ratio:0.53
T/O Rate:0.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1446
EPS(LYR):-0.5438
ROE:-12.80%
ROA:-9.70%
PB:2.35
PE(LYR):-5.24

Loading ...

Anavex delays filing quarterly report for March 31, 2026 quarter

Reuters
·
May 12

Anavex Life Sciences Corp expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
May 09

Anavex Life Sciences names Terrie Kellmeyer interim CEO, succeeding Missling

TIPRANKS
·
May 07

Anavex Life Sciences Names Interim CEO Amid Leadership Shift

TIPRANKS
·
May 06

Anavex names Terrie Kellmeyer interim CEO after Christopher Missling exit

Reuters
·
May 06

Press Release: Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer

Dow Jones
·
May 06

Anavex Life Sciences files Form 3 for director Axel Paeger

Reuters
·
May 02

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere

Reuters
·
Apr 14

Anavex plans pivotal studies of blarcamesine targeting autism-Alzheimer’s shared autophagy dysfunction

Reuters
·
Apr 14

Anavex Life Sciences to present at Needham Virtual Healthcare Conference

Reuters
·
Apr 07

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 31

BRIEF-Anavex Life Sciences Provides Comprehensive Regulatory Update

Reuters
·
Mar 30

Anavex keeps EMA talks after withdrawing EU blarcamesine filing for early Alzheimer’s

Reuters
·
Mar 30

Anavex Life Sciences Corp - Continues Dialogue With European Medicines Agency on Oral Blarcamesine for Early Alzheimer's Disease

THOMSON REUTERS
·
Mar 30

Ema's Chmp: Application for Initial Marketing Authorisation of Blarcamesine Anavex Was Withdrawn.

THOMSON REUTERS
·
Mar 27

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 27

Top Midday Decliners

MT Newswires Live
·
Mar 26

Anavex withdraws marketing authorization application for blarcamesine in the EU

TIPRANKS
·
Mar 25

Anavex Life Sciences Corp - Withdraws EU Marketing Authorization Application for Blarcamesine

THOMSON REUTERS
·
Mar 25

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease

GlobeNewswire
·
Mar 25